Prasco to market the authorized generic of Lilly’s Evista in USA

1 April 2014

Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly (NYSE: LLY) to market the authorized version of the latter’s osteoporosis drug Evista (raloxifene), in 60mg strength in the USA.

Prasco will begin shipping the product immediately. Financial details of the accord were not disclosed. Evista had annual sales of around $824 million in the USA, according to IMS data as of December 2013 quoted by Teva Pharmaceutical Industries (NYSE: TEVA), which recently gained US Food and Drug Administration for its generic version of the drug (The Pharma Letter March 4).

Third generics deal with Lilly

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK